Anti-Viral Drug Market 2022-2028

Description

List of Tables

Title:Global Anti-Viral Drug Market Size, Share, and Trends Analysis Report, by Type (Generic Anti-Viral Drugs and Branded Anti-Viral Drugs), by Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), by Application (HIV, Hepatitis, Herpes Virus, Influenza, and Others), Forecast Period (2022-2028).

The global anti-viral drug market is anticipated to grow at a CAGR of 4.0% during the forecast period. The anti-viral drugs have found their effective use in the treatment of viral infections, such as hepatitis, HIV, influenza, and others. The increased prevalence of these infections has surged both the demand as well as production on a wider level. Continuous R&D and investment by pharma companies in new drug development are opening a new path for market growth. Rising FDA approvals of the drug for the treatment of viral infection are also considered one of the prominent aspects of market development. For instance, in March 2022, GlaxoSmithKline Plc and Vir Biotechnology, Inc got approval from the USFDA for the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody due to Omicron BA.2 Subvariant. Moreover, in November 2019, the USFDA approved a supplemental New Drug Application for Roche's Xofluza for the treatment of influenza in patients 12 years of age and older. Likewise, in March 2019, GlaxoSmithKline Plc received approval from the National Medical Products Administration for Viread (tenofovir disoproxil fumarate), an oral antiviral drug for chronic hepatitis B treatment.

The global anti-viral drug market is segmented based on type, mechanism of action, and application. Based on type, the market is sub-segmented into generic anti-viral drugs and branded anti-viral drugs. Based on the mechanism of action, the market is further classified into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Similarly, based on application, it is classified into HIV, hepatitis, herpes virus, influenza, and others.

Geographically, the anti-viral drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific region is anticipated to exhibit a high CAGR during the forthcoming period. Growth is attributable to the frequent outbursts of viral diseases, namely, swine flu, dengue, and Ebola in emerging economies. The increasing number of generic pharmaceutical companies present in this region would contribute to the growth. Moreover, the increasing incidence of viral infection and surging approval and expected commercialization of novel medicines for viral infections are the crucial factors anticipated to drive the North American anti-viral drug market growth during the forecast period.

The major market players in the global anti-viral drug market include AbbVie, Inc., Merck & Co., GlaxoSmithKline plc, Pfizer Inc., Mylan NV, Dr. Reddy's Laboratories Ltd., Apotex Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals Ltd., Strides Pharma Science Ltd., Upsher-Smith Laboratories, among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global anti-viral drug is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of the market size and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Anti-Viral Drug Research and Analysis by Type
Global Anti-Viral Drug Research and Analysis by Mechanism of Action
Global Anti-Viral Drug Research and Analysis by Application

The Report Covers:

Comprehensive research methodology of the global anti-viral drug market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global anti-viral drug market.
Insights about market determinants that are stimulating the global anti-viral drug market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026757

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion
2.3. Porter's Analysis

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis

4. Market Segmentation

4.1. Global Anti-Viral Drug Market by Type
- 4.1.1. Generic Anti-Viral Drugs
- 4.1.2. Branded Anti-Viral Drugs
4.2. Global Anti-Viral Drug Market by Mechanism of Action
- 4.2.1. Nucleotide Polymerase Inhibitor
- 4.2.2. Reverse Transcriptase Inhibitors
- 4.2.3. Protease Inhibitors
- 4.2.4. Others
4.3. Global Anti-Viral Drug Market by Application
- 4.3.1. HIV
- 4.3.2. Hepatitis
- 4.3.3. Herpes Virus
- 4.3.4. Influenza
- 4.3.5. Others

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
- 5.4.1. Latin America
- 5.4.2. Middle East & Africa

6. Company Profiles

6.1. AbbVie, Inc.
6.2. Abbott Laboratories
6.3. Arbutus Biopharma Corp.
6.4. Aurobindo Pharma, Ltd.
6.5. BioCryst Pharmaceuticals, Inc.
6.6. Bristol-Myers Squibb Co.
6.7. Candel Therapeutics, Inc.
6.8. Cipla, Inc.
6.9. Dr. Reddy's Laboratories, Ltd.
6.10. F. Hoffmann-La Roche AG
6.11. Gilead Sciences, Inc.
6.12. GlaxoSmithKline PLC
6.13. Johnson & Johnson Services, Inc.
6.14. Merck & Co., Inc.
6.15. Mylan N.V.
6.16. Pfizer, Inc.
6.17. Sanofi S.A.
6.18. Sino Biopharmaceutical, Ltd.
6.19. The Hep B Company
6.20. Zydus Lifesciences, Ltd.